CK2 and PI(3)K are direct molecular targets of quercetin in chronic lymphocytic leukaemia

Despite the encouraging results of the innovative therapeutic treatments, complete remission is uncommon in patients affected by chronic lymphocytic leukaemia, which remains an essentially incurable disease. Recently, clinical trials based on BH3-mimetic drugs showed positive outcomes in subjects wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Maria, Milito, Alfonsina, Spagnuolo, Carmela, Carbone, Virginia, Rosén, Anders, Minasi, Paola, Lauria, Fabio, Russo, Gian Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522089/
https://www.ncbi.nlm.nih.gov/pubmed/28489572
http://dx.doi.org/10.18632/oncotarget.17246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522089/
https://www.ncbi.nlm.nih.gov/pubmed/28489572
http://dx.doi.org/10.18632/oncotarget.17246

Ejemplares similares